Infection with human Cytomegalovirus (CMV) continues to be a major threat for pregnant women, solid organ transplant recipients and patients with HIV-AIDS. Congenital CMV is the leading infectious cause of mental retardation and deafness. Although therapies for CMV can suppress virus replication, their prolonged use results in serious side effects and the emergence of resistant viruses. The available CMV inhibitors share the same mechanism of action - inhibition of viral DNA polymerase. There is an absolute need to identify new CMV inhibitors and to develop treatment strategies for CMV. The development of novel therapies for CMV could reduce morbidity and mortality in congenitally-infected children and the solid organ transplant population. Identification of novel compounds for CMV therapy is now possible because of the availability of large chemical libraries formatted as high-throughput screening (HTS) systems. The overall goals of this application (PAR-12-058) are to identify compounds that inhibit CMV replication using a quantitative HTS and a luciferase-recombinant CMV assay, to validate the specificity of the compounds for CMV using secondary and tertiary assays and to discover combination of anti-CMV agents by HTS to understand their mechanism of CMV inhibition. During the last several years we developed and validated sensitive and reproducible assays for quantification of CMV replication inhibition including a luciferase-recombinant CMV, luciferase-recombinant ganciclovir-resistant CMV, virus yield and DNA replication based on real-time PCR. These techniques have already been used extensively in our studies of CMV inhibitors such as artemisinins, and cardiac glycosides, two families of CMV inhibitors that differ in their mode of action and salinomycin. Our assays can be applied to screen the largest library of chemical probes in collaboration with the NIH and to identify chemical probes for the stage of virus replication in which these compounds act secondary and tertiary assays. The proposed investigations are likely to succeed because of our established experience in anti-viral assays and the expertise of NIH in HTS. The information derived from this application will have critical impact on CMV therapy. It may lead to the development of new concepts in CMV therapeutics by using compounds that inhibit a target different from the viral DNA polymerase and by implementing combination anti-CMV therapy.
Congenital infection with Cytomegalovirus (CMV) is the leading infectious cause of deafness and mental retardation in children worldwide. Treatment options for CMV infection are limited, and it is critical to develop new therapeutic strategies against this pathogen CMV. The overall aim of this proposal is to identify new chemical probes for CMV therapy using high-throughput screening of several large chemical libraries, to validate the hits probes and perform mechanistic studies of the newly-identified chemical probes to identify combination of probes that could be used for CMV therapy.
|Barger-Kamate, Breanna; Forman, Michael; Sangare, Cheik Oumar et al. (2016) Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children. J Clin Virol 77:40-5|
|Mukhopadhyay, Rupkatha; Roy, Sujayita; Venkatadri, Rajkumar et al. (2016) Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus. PLoS Pathog 12:e1005717|
|Arav-Boger, Ravit (2015) Strain Variation and Disease Severity in Congenital Cytomegalovirus Infection: In Search of a Viral Marker. Infect Dis Clin North Am 29:401-14|
|McClain, Lora; Zhi, Yun; Cheng, Hoyee et al. (2015) Broad-spectrum non-nucleoside inhibitors of human herpesviruses. Antiviral Res 121:16-23|